BioPharmSignal logoBioPharmSignal

Company Profile

Fate Therapeutics Stock Price, News & Catalysts

Ticker:
FATE
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

2.52 USD (+3.28%)

Close

Last updated: September 17, 2026

300M USD

Market cap

Why the stock is moving

Following the latest company update, “Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026”, FATE closed up 3.83% at $2.44 on Sep 16, 2026. The move occurred in the trading session associated with this company update.

Company overview

iPSC-Derived Cell Therapy Platform

Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells.

FT819

FT819 is an iPSC-derived CD19 CAR T-cell therapy for autoimmune disease. The platform is intended to provide standardized manufacturing and repeatable dosing without patient-specific cell collection.

Lupus Development

Clinical work includes systemic lupus erythematosus and lupus nephritis, using reduced conditioning to improve treatment accessibility.

Broader Pipeline

FT839 is an earlier program designed for broad targeting of hematologic malignancies and autoimmune disease without conventional conditioning chemotherapy.

Future catalysts

    Recent news

    1. 01

      Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

    2. 02

      Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

    3. 03

      Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

    4. 04

      Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

    5. 05

      Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    ACHL

    Achilles Therapeutics

    ADAP

    Adaptimmune Therapeutics plc

    ACET

    Adicet Bio

    ALVR

    AlloVir

    ALLO

    Allogene Therapeutics

    ACLX

    Arcellx

    ATRA

    Atara Biotherapeutics, Inc.

    AUTL

    Autolus Therapeutics plc

    Frequently Asked Questions

    What is the current stock price of Fate Therapeutics (FATE)?

    Fate Therapeutics (FATE) most recently closed at 2.52 USD, a +3.28% move versus the previous session.

    What is the market cap of Fate Therapeutics (FATE)?

    Fate Therapeutics currently has a market capitalization of 300M USD on BioPharmSignal.

    What does Fate Therapeutics do?

    iPSC-Derived Cell Therapy Platform Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells. FT819 FT819 is an iPSC-derived CD19 CAR T-cell therapy for autoimmune disease. The platform is intended to provide standardized manufacturing and repeatable dosing without patient-specific cell...

    On which exchange is FATE stock listed?

    Fate Therapeutics (FATE) is associated with NASDAQ, United States, Biopharma.

    What is Derived?

    iPSC-Derived Cell Therapy Platform Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells.

    Which conditions is Fate Therapeutics targeting with Derived?

    iPSC-Derived Cell Therapy Platform Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells. FT819 FT819 is an iPSC-derived CD19 CAR T-cell therapy for autoimmune disease. The platform is intended to provide standardized manufacturing and repeatable dosing without patient-specific cell...

    What is Cell?

    iPSC-Derived Cell Therapy Platform Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells.

    What is Therapy?

    iPSC-Derived Cell Therapy Platform Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells.